Fact-checked by Grok 2 weeks ago

Nuclear transfer

Nuclear transfer is a biotechnological technique in which the nucleus of a donor , often , is transplanted into an enucleated or early , allowing the donor to be reprogrammed by the recipient to direct development. The procedure, foundational to , was first demonstrated in amphibians in the mid-20th century but achieved mammalian success with the 1996 birth of the sheep, derived from an adult mammary gland nucleus via (). This breakthrough enabled reproductive across species including , mice, and , while also supporting therapeutic applications like patient-specific embryonic stem cells for disease modeling and potential . However, persistent challenges include extremely low efficiency—often below 5% live births in mammals due to incomplete epigenetic reprogramming—frequent developmental abnormalities, and accelerated aging in clones, as evidenced by Dolly's early-onset and at age six. Ethical debates center on risks of human reproductive , animal welfare, and the technique's potential for misuse, prompting bans in many jurisdictions despite its utility in research. Advances in chemical reprogramming and interspecies transfers continue to refine the method, though empirical data underscore its limitations over hype-driven narratives.

History

Early Pioneering Experiments

In 1938, German embryologist proposed a conceptual experiment to test the developmental equivalence of nuclei across differentiation stages, suggesting the transplantation of a nucleus from a fully differentiated cell into an enucleated , which he described as a "fantastical experiment" due to technical challenges. This idea stemmed from his earlier organizer experiments in the , which highlighted inductive interactions between embryonic tissues, but it specifically envisioned nuclear transfer as a means to isolate the 's role from cytoplasmic influences. Spemann's proposal remained unimplemented during his lifetime, serving as a theoretical cornerstone for investigating whether somatic nuclei retain totipotent potential akin to zygotic nuclei. The first practical achievements in nuclear transfer occurred in 1952, when American scientists Robert Briggs and Thomas J. King successfully transplanted living nuclei from blastula-stage cells into enucleated eggs of the frog Rana pipiens. Their method involved ultraviolet pricking to destroy the egg's nucleus, confirmed by lack of cleavage in 99% of treated eggs (631 out of 638), followed by micropipette injection of a donor nucleus from advanced blastula or early gastrula cells (stages 8–10). Over 50% of injected eggs cleaved, with 74% of resulting blastulae undergoing normal gastrulation; among these, approximately 50% developed into morphologically normal embryos reaching tadpole stages (up to stage 25), including feeding tadpoles, while others exhibited defects like microcephaly. These outcomes demonstrated that blastula nuclei could be reprogrammed by egg cytoplasm to support complete embryonic development, with no haploid clones observed and occasional polyploidy attributed to endomitosis. Briggs and King's follow-up experiments through the further revealed stage-dependent restrictions on potency in amphibians. Nuclei from progressively later stages—such as late gastrula or neurula —yielded declining success rates, with nuclei producing only partial embryos featuring normal endodermal derivatives but severe defects in mesodermal and ectodermal structures, indicating irreversible -induced barriers to totipotency. For example, while blastula transfers achieved up to 40–50% normal development to tadpoles, neurula-stage transfers rarely exceeded 10–20% viable embryos, often arresting at early . These findings empirically established that correlates with reduced reprogrammability, laying groundwork for understanding epigenetic constraints without invoking mammalian applications.

Development in Mammals and Dolly the Sheep

Efforts to achieve nuclear transfer in mammals during the and early initially relied on nuclei from early embryonic blastomeres rather than differentiated cells. In 1986, Steen Willadsen reported the first successful of sheep using nuclear transfer of a blastomere from an 8- to 16-cell embryo into an enucleated , inducing fusion with Sendai virus and achieving live births. Similar blastomere nuclear transfers were extended to cows and other species, demonstrating totipotency in early embryonic cells but limited by the inability to reprogram nuclei from more differentiated sources. These techniques built on precedents but faced challenges in mammals due to stricter epigenetic barriers and lower developmental success rates. By the mid-1990s, researchers at the in advanced toward using cultured fetal and embryonic cells for nuclear transfer in sheep. In 1995, and Keith Campbell's team produced lambs Megan and Morag via nuclear transfer from nine-day-old embryonic disc cells, marking the first clones from cultured, non-blastomere embryonic sources and highlighting the potential for synchronization. These experiments used electrical methods initially developed by Willadsen, improving enucleation and efficiency over chemical agents. The breakthrough with Dolly represented the first use of a fully differentiated nucleus for mammalian . Wilmut's team transferred the nucleus from an sheep epithelial cell into an enucleated Scottish Blackface , employing serum starvation of donor cells to them in the quiescent G0/G1 phase, which facilitated nuclear reprogramming by minimizing transcriptional conflicts. Fusion and activation were achieved via electrical pulses, followed by and transfer to surrogate mothers. After 277 reconstructed embryos and 29 transfers yielding one viable pregnancy, was born on July 5, 1996, and publicly announced by the on February 22, 1997. This achievement confirmed that mammalian nuclei could direct full-term development, overturning assumptions about irreversible .

Post-Dolly Advancements

Following the 1996 birth of Dolly the sheep, somatic cell nuclear transfer (SCNT) expanded rapidly to diverse mammalian species, demonstrating the technique's versatility beyond sheep. In July 1998, Teruhiko Wakayama and colleagues at the University of Hawaii reported the first successful cloning of mice using cumulus cells—follicular cells surrounding oocytes—as nuclear donors, yielding 22 cloned pups from over 100 transfers, with some second-generation clones viable. This Honolulu technique, involving piezo-assisted micromanipulation for enucleation and strontium activation of reconstructed oocytes, addressed challenges like small oocyte size and achieved reproducible results, contrasting earlier failures. By 2000, SCNT produced the first cloned piglets and calves, with subsequent successes in goats, rabbits, mules, horses, and rats, culminating in over 20 mammalian species cloned by the mid-2000s. Key milestones highlighted SCNT's application to pets and conservation. In December 2001, researchers at announced the birth of CC (), the first cloned domestic cat, derived from cumulus cells of a calico donor and gestated in a surrogate; despite epigenetic differences causing dissimilar coat patterns, CC developed normally and lived to 18 years. The same year, Advanced Cell Technology cloned , the first endangered species—a ( gaurus), an Asian wild —using frozen skin cells from a deceased specimen transferred into bovine oocytes and carried by a domestic cow surrogate; was born via cesarean on January 8 but died 48 hours later from , unrelated to cloning defects. These events underscored SCNT's potential for preserving , though high perinatal losses persisted. Human SCNT efforts encountered ethical and scientific hurdles. In May 2005, South Korean researcher published claims of deriving 11 patient-specific human lines via SCNT, building on a 2004 report of cloned human blastocysts; however, investigations later confirmed data fabrication, oocyte procurement ethics violations, and no viable lines produced, leading to Hwang's dismissal and fraud charges. Protocol refinements post-Dolly incrementally boosted efficiency from Dolly's <1% live birth rate (1 viable from 277 fused couplets). Innovations like donor cell serum starvation for quiescence, refined micromanipulation, and histone deacetylase inhibitors for epigenetic remodeling raised success to 5-10% in optimized systems for mice and cattle by the late 2000s, though overall yields remained low due to incomplete nuclear reprogramming. These gains facilitated agricultural applications but highlighted persistent barriers like placental abnormalities.

Techniques and Methods

Somatic Cell Nuclear Transfer

Somatic cell nuclear transfer (SCNT) is a technique that replaces the nucleus of an enucleated oocyte with the nucleus of a donor somatic cell, enabling the assessment of whether the differentiated somatic genome can be reprogrammed to a totipotent state capable of directing full organismal development through the oocyte's cytoplasmic environment. This process tests the potential for epigenetic resetting without gametic intermediates, relying on the oocyte's factors to erase somatic restrictions and restore developmental pluripotency. Success rates vary by species and cell type, with efficiencies often below 5% in mammals due to incomplete reprogramming. The standard SCNT protocol initiates with donor somatic cell collection, typically from skin fibroblasts or cumulus cells, followed by in vitro culture to arrest cells in quiescence (G0/G1 phase) for optimal reprogramming compatibility. A metaphase II-arrested oocyte is then enucleated via micromanipulation, aspirating the haploid nucleus and polar body under microscopy to create a cytoplast devoid of maternal DNA. The isolated donor nucleus, either as an intact cell or purified, is transferred into the perivitelline space or directly injected into the cytoplast. Fusion occurs via electrical pulsing or chemical agents to integrate the nucleus, followed by artificial activation—using ions like strontium or calcium—to mimic fertilization and resume meiosis, initiating embryonic cleavage. Resulting embryos are cultured in vitro to the blastocyst stage before transfer or analysis. A scalable variant, handmade cloning (HMC), modifies SCNT by forgoing micromanipulators: oocytes are briefly exposed to demecolcine for chemical enucleation, zona pellucida is removed manually, and bisected cytoplasts are fused with donor cells using phytohemagglutinin-assisted adhesion and electrical pulses. This approach reduces equipment demands and operator skill requirements, achieving comparable blastocyst yields to traditional SCNT in species like cattle and pigs while enabling higher throughput for agricultural applications. HMC has demonstrated pregnancy rates up to 40% in optimized bovine systems.

Pronuclear Transfer and Mitochondrial Replacement

Pronuclear transfer is a mitochondrial replacement technique in which the pronuclei—containing the nuclear DNA—from a zygote formed by fertilizing an egg with faulty mitochondria are transplanted into an enucleated donor oocyte with healthy mitochondria. This process, performed shortly after fertilization, replaces the defective mitochondrial DNA (mtDNA) while preserving the parents' nuclear genome, aiming to prevent transmission of maternally inherited mitochondrial disorders. The technique was refined in the 2010s through preclinical studies demonstrating low mtDNA carryover rates, typically under 2% in resulting blastocysts. In the United Kingdom, mitochondrial replacement therapies, including , received parliamentary approval on February 3, 2015, making the UK the first country to legalize such procedures for clinical use under strict regulatory oversight by the . This authorization enabled treatments to avert severe heritable conditions caused by , such as , a progressive neurodegenerative disorder affecting energy production in cells. By substituting healthy mitochondria, pronuclear transfer causally interrupts the inheritance of pathogenic , which occur in up to 1 in 5,000 live births and lead to disorders with high morbidity, including Leigh syndrome variants linked to mutations like m.8993T>G. A July 16, 2025, study published in the New England Journal of Medicine reported the viability of pronuclear transfer in embryos, with eight healthy babies (four girls and four boys, including one set of twins) born to seven women at high risk of transmitting mtDNA diseases. These outcomes, from 22 women carrying pathogenic mtDNA variants, integrated pronuclear transfer with , confirming embryo compatibility and reduced levels post-transfer. The procedure's success in producing live births without evident mitochondrial dysfunction underscores its potential to mitigate disorders like , though long-term monitoring remains essential due to the novelty of mtDNA modification.

Interspecies and Other Variants

Interspecies (iSCNT) involves transferring a from one into an enucleated from a different , aiming to overcome limitations such as shortages of donor oocytes in research. This approach has been explored primarily for generating embryonic cells, particularly by inserting nuclei into oocytes like those from or bovines, as oocytes are scarce and ethically restricted. For instance, in 2003, embryonic cells were successfully derived from blastocysts formed by transferring nuclei into rabbit enucleated oocytes, demonstrating partial despite mismatch. Success rates remain low, with development typically arresting before implantation, and iSCNT is more viable between closely related that can interbreed, while taxonomically distant combinations fail due to incompatibilities. A key barrier in iSCNT is mitonuclear incompatibility, where the donor nucleus interacts poorly with the recipient oocyte's mitochondrial DNA, disrupting energy production and embryonic development.30298-4) This mismatch impairs mitonuclear communication, leading to oxidative stress, altered respiration, and failure in reprogramming the donor genome. Recent analyses as of April 2025 emphasize these interconnected complexities, including irregular transcriptome reprogramming and epigenetic barriers that hinder full-term viability in cross-species embryos. A 2024 meta-analysis of 143 iSCNT studies confirmed that while blastocyst formation is achievable in some pairings (e.g., murine nuclei into bovine oocytes), progression beyond early stages is rare without species-specific adaptations. Other variants of nuclear transfer include chemically assisted enucleation, which uses antimitotic agents like demecolcine or to extrude the oocyte's plate without , simplifying the procedure and potentially improving cytoplast quality for . These methods increase activity in cytoplasts, enhancing nuclear transfer efficiency compared to traditional micromanipulation, though they do not fully resolve species barriers in iSCNT. Ooplast pre—treating enucleated oocytes with activation stimuli prior to nuclear insertion—has also been tested to synchronize donor nuclei and boost preimplantation development rates, raising them from approximately 15% to 56% in some mammalian models. Such techniques offer procedural alternatives but underscore ongoing challenges in achieving stable interspecies hybrids.

Biological Mechanisms

Nuclear Reprogramming Process

Upon transfer of a into the enucleated , the donor is exposed to the oocyte's cytoplasmic environment, which triggers immediate structural remodeling. Within approximately 30 minutes, the undergoes breakdown (NEBD), mediated by high levels of (MPF) present in the metaphase II-arrested . This is rapidly followed by premature chromosome condensation (PCC), where the forms condensed, -like chromosomes, facilitating the initial erasure of somatic cellular identity. Subsequent to PCC, the chromosomes decondense, and a new reforms, allowing the to integrate with the host oocyte's machinery and resume a compatible with early embryogenesis. This phase transitions the reprogrammed toward totipotency, enabling symmetric divisions as the construct is activated to mimic fertilization. As progresses, culminates in zygotic activation (ZGA), the point at which the embryonic initiates widespread transcription to support further development; in many mammalian species, including bovines and , major ZGA occurs around the 4- to 8-cell stage. In cloned embryos, however, ZGA is often delayed or incomplete compared to fertilized counterparts, reflecting inefficiencies in the reprogramming reset. Time-lapse imaging studies of nuclear transfer embryos demonstrate that reprogramming failures frequently manifest as early developmental arrests, such as stalled at the 2- to 4-cell stage, attributable to errors in chromosome segregation or insufficient transcriptional activation from the donor . These observations, derived from live-cell monitoring in like mice and bovines, underscore the nature of successful nuclear reset, with arrest rates exceeding 90% in many protocols due to persistent constraints.

Epigenetic Factors and Barriers

In (SCNT), epigenetic barriers arise primarily from the persistence of somatic cell-specific modifications on the donor nucleus, which resist by oocyte factors. These include aberrant patterns and modifications that fail to be fully erased, leading to dysregulated during early embryonic development. Unlike natural fertilization, where paternal and maternal genomes undergo complementary demethylation, SCNT embryos exhibit delayed and incomplete global , particularly at imprinted loci, resulting in imprinting errors that disrupt post-implantation viability. Somatic DNA methylation marks, such as hypermethylation at promoter regions of developmental genes, are incompletely erased in SCNT, hindering the activation of pluripotency networks. Studies in models show that cloned embryos retain elevated levels compared to fertilized counterparts, correlating with failed remethylation waves and developmental arrest. modifications exacerbate this: persistent and repressive marks from the donor suppress essential embryonic genes, including those involved in formation, and contribute to imprinting disruptions like loss of at paternally imprinted regions. These barriers manifest as biallelic expression or silencing errors at loci such as Igf2r and Sfmbt2, directly impeding progression beyond the stage. X-chromosome reactivation poses a specific challenge in SCNT embryos, where the inactivated X (Xi) from the somatic donor fails to properly reactivate and re-inactivate, leading to ectopic expression and dosage imbalances. factors, including transcription factors like Oct4, play a critical role in attempting to drive this reactivation, but somatic epigenetic locks—such as lingering on Xi—often result in asynchronous or incomplete X-chromosome counting and inactivation. Gain-of-function approaches enhancing Oct4 in the oocyte microenvironment have shown partial rescue of reactivation dynamics during initial cleavages, underscoring the oocyte's limited capacity to overcome somatic Xi repression without additional interventions. These epigenetic obstacles causally underlie the low efficiency of SCNT, with live birth rates typically below 5% despite frequent production of viable blastocysts, as persistent marks trigger transcriptional noise and apoptotic cascades post-implantation. Targeted erasure of barriers, such as demethylation or knockdown, has increased full-term development in mice from under 2% to over 10% in optimized protocols, confirming their rate-limiting role.

Applications

Reproductive Cloning in Animals

Reproductive cloning through (SCNT) in animals produces genetically identical offspring by inserting the of a from a donor into an enucleated , which is then matured, activated, and implanted into a . This method replicates the donor's genome exactly, bypassing the and variability inherent in conventional . In livestock, it primarily serves to propagate elite individuals with superior production traits, such as high in bulls or enhanced dairy/beef yields, enabling rapid dissemination of proven genetics to improve herd performance without repeated progeny testing. A key application involves cloning male breeders, particularly , to generate for (), multiplying elite traits across large populations efficiently. For example, in , clones of superior have yielded with parameters equivalent to the donor, including and viability, supporting normal production. In , from a cloned produced in 2019 achieved a 55% rate upon , comparable to non-cloned counterparts, and has sired healthy offspring without detectable abnormalities in growth or . By 2021, such enabled the birth of 12 from multiple , validating its use for enhancement in resource-limited settings where elite availability is scarce. This approach preserves exact genetic profiles of top performers—such as disease resistance or high-yield phenotypes—avoiding the dilution from crossbreeding and accelerating trait fixation in commercial herds. Despite efficiencies remaining low at 0-10% live births per transferred due to failures, SCNT has facilitated the production of viable clones in species like and for semen banking, contributing to sustained genetic improvement in . Cloned bulls undergo screening for testicular development and before deployment, ensuring practical utility in programs.

Therapeutic Cloning for Stem Cells

Therapeutic cloning, also known as (SCNT) for production, involves transferring the from a patient's into an enucleated to generate an early-stage embryo. The resulting construct is chemically or electrically activated to mimic fertilization, allowing it to divide and develop into a without implantation. The (ICM) of the is then isolated and cultured to derive embryonic cells (ESCs) that are genetically identical to the donor, enabling potential autologous applications. A landmark achievement occurred in 2013 when Shoukhrat Mitalipov and colleagues at successfully derived the first human ESCs via SCNT, using fetal somatic cells as nuclear donors and oocytes from separate donors. This process yielded stable pluripotent stem cell lines capable of differentiating into multiple cell types, demonstrating effective nuclear reprogramming by oocyte cytoplasmic factors. Subsequent refinements in 2014 enabled SCNT-derived ESCs from adult dermal fibroblasts, confirming applicability to post-reproductive age donors and addressing prior technical barriers like incomplete reprogramming in human systems.00571-0) These patient-matched SCNT ESCs offer advantages over induced pluripotent cells (iPSCs) by leveraging the natural reprogramming environment of the , which may reduce epigenetic abnormalities and genetic mutations associated with integration in iPSCs. The isogenic nature of SCNT-derived cells minimizes immune rejection risks in potential therapies, as they share the patient's nuclear genome, unlike allogeneic ESCs or iPSCs with donor variability. However, SCNT requires human , limiting scalability compared to iPSCs generated from accessible cells. In research applications, SCNT ESCs facilitate disease modeling by creating genetically precise cellular models of patient-specific conditions, such as mitochondrial disorders or neurodegenerative diseases, without confounding genetic heterogeneity. They also support high-throughput drug testing on isogenic cell lines, potentially improving predictive accuracy for therapeutic responses over heterogeneous models. Despite these potentials, clinical translation remains limited by low blastocyst formation rates (typically under 20%) and ethical constraints on oocyte sourcing, with ongoing efforts focused on efficiency enhancements through histone deacetylase inhibitors and optimized activation protocols.

Agricultural and Conservation Uses

Somatic cell nuclear transfer (SCNT) facilitates the cloning of elite to propagate desirable agricultural traits, such as enhanced growth rates, production, or quality, enabling farmers to rapidly multiply high-value without reliance on traditional cycles. In , SCNT has been applied since the late to duplicate animals with superior phenotypes, accelerating the dissemination of traits like resistance or feed efficiency across herds. This approach supports precision in including and pigs, where cloned inherit the donor's , preserving exact genetic combinations for commercial farming. SCNT also enables the production of transgenic , particularly pigs genetically modified for , by transferring nuclei from edited cells into enucleated oocytes. In 2016, researchers generated multi-transgenic pigs via serial nuclear transfer, incorporating up to ten genetic modifications to mitigate hyperacute rejection in potential transplants, with clones expressing human complement regulators and lacking porcine antigens. Subsequent advancements in the have produced herds of cloned, gene-edited pigs—such as those with CRISPR-induced knockouts of alpha-gal epitopes—bred on farms to yield viable donor organs, demonstrating scalable agricultural integration of for biomedical output. In , SCNT addresses genetic erosion in by resurrecting lost lineages from preserved cells, thereby expanding effective population sizes and countering . A application occurred in 2020, when interspecies SCNT produced , the first cloned (Mustela nigripes), using nucleus from a female (Willa) frozen since 1988 transferred into domestic oocytes; this clone carries 50 novel single-nucleotide polymorphisms absent in the extant population, derived from only seven wild-caught founders in the 1980s. In November 2024, a cloned named gave birth to two kits, confirming the reproductive competence of such clones and their potential to contribute fertile , further mitigating the genetic that has reduced heterozygosity in captive ferrets by over 50% since reintroduction. This technique empirically restores allelic diversity, as modeled in ferret simulations showing increased long-term viability when clones comprise 10-20% of breeding pairs.

Human Medical Therapies

Mitochondrial replacement therapy (MRT), a form of pronuclear transfer, has been applied to prevent the inheritance of mitochondrial DNA (mtDNA) diseases in humans. This technique involves transferring the pronuclei from a zygote created by the prospective mother's egg and father's sperm into an enucleated donor egg with healthy mitochondria, thereby replacing defective mtDNA while preserving nuclear DNA. The first human birth using MRT occurred in 2016, when a U.S. clinician performed the procedure in Mexico for a Jordanian couple at risk of Leigh syndrome. In the United Kingdom, where MRT was legalized in 2015, the first births were reported in 2023, followed by confirmation in July 2025 of eight healthy infants born via pronuclear transfer combined with preimplantation genetic testing. These children exhibited low or undetectable levels of pathogenic mtDNA (ranging from 0% to 16%), with all meeting developmental milestones, demonstrating initial clinical viability for averting maternally inherited mitochondrial disorders otherwise untreatable by direct genetic repair. Nuclear transfer techniques have also advanced treatments for human infertility, particularly in cases of oocyte shortages or diminished . In September 2025, researchers at (OHSU) reported generating functional, fertilizable egg-like cells from human skin cells via (SCNT), where a diploid skin was inserted into an enucleated donor , followed by experimental to induce haploidy and oocyte maturation. These induced oocytes supported fertilization and early development up to the stage, offering a potential autologous solution for women unable to produce viable eggs due to age-related decline or genetic factors. This approach causally addresses empirical barriers in assisted reproduction, such as the global scarcity of donor oocytes and the inability of conventional IVF to generate genetically related gametes from somatic sources, though full-term viability in humans remains unachieved pending further trials. Such NT-based therapies empirically target root causes like mtDNA in mitochondrial diseases—where mutant mtDNA loads exceed 60-90% thresholds for pathology—and incompetence in , which affects up to 10-15% of reproductive-age women and correlates with rates over 50% in . Unlike donor IVF, NT preserves nuclear genetic identity, reducing immunological risks and enabling biological parenthood without third-party gametes. Ongoing refinements, including carryover minimization in to below 2% mutant mtDNA, underscore causal efficacy in disrupting disease transmission chains empirically resistant to alternatives like PGD alone.

Achievements and Empirical Successes

Successful Cloning Across Species

The first mammal cloned via (SCNT) from an adult was the sheep, born on July 5, 1996, using a from an adult transferred into an enucleated . This breakthrough demonstrated that differentiated mammalian s could be reprogrammed to support full-term development, paving the way for in additional . Following Dolly, SCNT succeeded in producing viable offspring across more than 20 mammalian , including , pigs, , mice, rabbits, cats, dogs, horses, mules, ferrets, and . Notable early examples include cloned calves born in 1998 and pigs in 2000, confirming the technique's applicability beyond sheep. A landmark achievement occurred in 2018 with the birth of , the first cloned by SCNT; these long-tailed monkeys were derived from fetal cells and survived into adulthood under care.30057-6) Cloning efficiencies, defined as live birth rates per transferred , generally range from 1% to 5% across , with bovine SCNT showing the highest reported rates of up to 9.3% in select donor cell lines and protocols. By the 2020s, commercial SCNT applications had resulted in thousands of cloned animals, predominantly and for propagation and elite breeding stock. These efforts, led by companies in the United States, , , and , underscore scalable production for agricultural enhancement.

Contributions to Regenerative Medicine

(SCNT) facilitates the derivation of nuclear transfer embryonic stem cells (ntESCs) that are genetically matched to patients, offering a pathway for autologous therapies in by circumventing immune rejection issues inherent in allogeneic transplants. These ntESCs can differentiate into various -specific lineages, supporting applications in repairing damaged organs or replacing dysfunctional s. For instance, in preclinical models, SCNT-derived cells have been used to generate transplantable s, demonstrating potential for treating conditions involving degeneration. In disease modeling, SCNT enables the creation of patient-specific cellular systems to recapitulate pathologies such as and , allowing causal investigation of disease mechanisms without ethical constraints of human embryos. By nuclei from affected individuals, researchers can produce ntESC lines that maintain donor , facilitating studies on dopaminergic neuron loss in Parkinson's or beta-cell dysfunction in , which inform targeted therapeutic interventions. This approach complements (iPSC) technologies, where hybrid strategies leveraging SCNT's complete capacity address limitations in iPSC epigenetic fidelity. SCNT-mediated provides empirical insights into epigenetic dynamics underlying aging and cellular , revealing barriers like incomplete that must be overcome for efficient totipotency restoration. These findings enable causal analyses of age-associated epigenetic drift, supporting regenerative strategies that partially reverse markers in cells, as observed in mammalian experiments where donor age influences clone viability but can mitigate some . Such mechanistic understanding advances by optimizing protocols for generating youthful, functional cells for transplantation.

Insights into Developmental Biology

Somatic cell nuclear transfer (SCNT) experiments have empirically demonstrated that is not an absolute, irreversible process, challenging a longstanding in that posited nuclei undergo permanent modifications precluding totipotency upon differentiation. Early NT studies by Spemann and Mangold in the 1920s, followed by Briggs and King in the 1950s, initially suggested restrictions but later refinements showed differentiated nuclei could support full embryonic development when transferred to enucleated eggs, as confirmed in mammalian with the sheep in 1996. This reversal relies on factors that erase somatic epigenetic marks, enabling to a totipotent state capable of generating all cell lineages, including extra-embryonic tissues. NT has illuminated critical windows for totipotency acquisition, revealing that occurs in discrete phases post-transfer, with rapid and activation of embryonic genes within hours.01020-7) Single-cell analyses indicate totipotency is transiently reacquired before pluripotency stabilizes, highlighting a narrow temporal window where nuclei synchronize with oocyte machinery to bypass barriers. These findings underscore causal mechanisms of developmental plasticity, where totipotency emerges from dynamic interplay of transcription factors and epigenetic erasure rather than fixed genomic states. Contrary to early concerns that cloned organisms inherit shortened telomeres from aged donors, leading to premature aging, NT reveals telomere elongation during preimplantation stages via activation in the embryonic milieu, resetting lengths comparable to natural zygotes. This debunks the of obligatory telomere attrition in , as evidenced by viable clones exhibiting telomere maintenance or extension, independent of donor age. Comprehensive 2025 reviews tracing milestones from Hans Spemann's 1938 organizer graft experiments to modern SCNT affirm these insights, emphasizing how a century of empirical data has redefined as reversible through oocyte-mediated causal .

Challenges and Scientific Limitations

Low Efficiency and Technical Hurdles

Somatic cell nuclear transfer (SCNT) procedures consistently demonstrate low developmental efficiency, with formation rates typically ranging from 20% to 50% across mammalian species such as bovines and sheep, while live birth rates per reconstructed often fall below 5% due to failures in oocyte activation and early embryonic arrest. These rates reflect persistent barriers, including incomplete remodeling and suboptimal cytoplasmic conditions in recipient s, which hinder progression beyond the preimplantation stage. A primary causal factor is the asynchronous cell cycle stages between the donor somatic nucleus—typically in —and the enucleated paused at II, leading to mismatched signals that promote chromosomal instability, such as from abnormal segregation during early cleavages. This asynchrony disrupts epigenetic erasure and re-establishment, resulting in aberrant patterns that cause developmental failure independent of post-birth viability issues. rates are exacerbated in SCNT embryos compared to fertilized counterparts, with studies linking microduplications in donor cells to reduced competency. Efficiency is heavily dependent on oocyte quality, as inferior cytoplasmic maturity or mitochondrial function in recipient eggs amplifies reprogramming deficits; in vivo-matured oocytes yield higher blastocyst rates (up to 43%) than in vitro counterparts (around 21%). To address these hurdles, recent technical refinements as of 2025 incorporate pre-implantation aids like optimized protocols and post-implantation supports, such as inhibitors or Wnt pathway modulation, achieving exceptional full-term development rates nearing 30% in select porcine models by mitigating epigenetic barriers. However, these advances remain species-specific and do not universally resolve underlying causal mismatches in nuclear-cytoplasmic interactions.

Health Abnormalities in Clones

Cloned animals produced via (SCNT) frequently exhibit developmental and postnatal health abnormalities, primarily attributed to incomplete epigenetic reprogramming of the donor nucleus, which disrupts normal patterns during embryogenesis. These issues manifest as , , and immune dysfunction, contributing to elevated rates of , , and neonatal mortality. For instance, in clones such as and sheep, placental defects including underdeveloped cotyledons and excessive fluid accumulation (hydroallantois) are common, impairing nutrient exchange and leading to intrauterine growth dysregulation. A prominent is large offspring syndrome (LOS), characterized by fetal overgrowth, expanded organs, and hyperplasia, often resulting in dystocia and respiratory distress at birth. LOS arises from aberrant signaling and overproliferation, with affected clones showing asynchronous organ maturation and cardiovascular anomalies. In bovine SCNT, LOS-affected calves display and , with survival rates post-birth often below 50% without intervention. These defects persist into adulthood in survivors, including hepatic and renal , underscoring the protracted impact of reprogramming failures. The first cloned mammal, the sheep, exemplified early concerns with premature aging indicators, developing in her knee at approximately 5.5 years—earlier than typical for sheep—and exhibiting shortened consistent with the donor cell's age. was euthanized at 6.5 years due to progressive lung disease, fueling speculation of accelerated from telomere attrition and cumulative epigenetic errors. However, subsequent analyses of cloned sheep cohorts, including replicates from similar cell lines, revealed no consistent telomere shortening or shortened lifespans, with many reaching ages equivalent to controls (9-13 years) without overt degenerative diseases. Mitochondrial , resulting from carryover of donor cell mitochondria into the recipient , exacerbates these vulnerabilities by introducing mtDNA incompatibilities that impair and cellular energetics. In SCNT embryos, mismatched mitochondrial-nuclear interactions can trigger accumulation, promoting in trophoblast cells and contributing to placental . Studies in porcine and bovine models link higher donor mtDNA persistence to increased incidence of metabolic disorders and reduced viability, though serial recloning mitigates some heteroplasmy effects. Immune abnormalities, such as thymic and T-cell deficiencies observed in 10-30% of surviving clones across , further highlight the interplay of epigenetic and mitochondrial factors in postnatal morbidity.

Resource and Scalability Issues

Somatic cell nuclear transfer (SCNT) demands substantial quantities of , often hundreds per successful clone, owing to efficiencies typically ranging from 0% to 10% for live births after . This resource intensity arises from high rates of embryonic failure during and , constraining large-scale application even in where oocytes can be sourced from materials. For equines, oocyte availability remains a primary despite commercial viability in niche cases. Commercial SCNT for animals incurs costs exceeding $50,000 for or and $85,000 for horses, reflecting the labor, materials, and repeated attempts required amid procedural variability. These expenses, coupled with inconsistent outcomes, restrict operations to specialized firms like ViaGen, with limited widespread adoption for or . Scalability is further hampered by the technique's dependence on skilled micromanipulation and oocyte quality, which cannot readily expand without proportional increases in biological inputs. Induced pluripotent stem cells (iPSCs) present a competing approach for generating patient-specific cells, bypassing requirements and enabling higher throughput via chemical or of somatic cells. While SCNT yields genetically identical organisms or embryos, iPSCs facilitate scalable into tissues without the resource burdens of nuclear transfer, diminishing SCNT's practicality for therapeutic or expansion. This contrast underscores SCNT's niche persistence in full organism cloning over broader cellular production.

Ethical and Societal Controversies

Debates on Reproductive Cloning

Reproductive via nuclear transfer involves creating a genetically identical offspring from a nucleus inserted into an enucleated , sparking intense debate over its application in animals and potential extension to humans. Proponents argue it could expand reproductive options for infertile couples, individuals with deceased partners, or same-sex pairs unable to produce genetically related children through conventional means, framing it as an extension of procreative liberty akin to assisted reproductive technologies. They contend that empirical risks, such as developmental abnormalities observed in animal clones, are overstated relative to early fertilization (IVF), which initially carried a 30-40% elevated risk of birth defects but improved with refinement, suggesting cloning efficiencies could similarly advance through iterative research. Opponents, representing the predominant scientific and ethical , emphasize profound risks to cloned individuals, including psychological harms from diminished uniqueness and identity confusion, as clones may grapple with predetermined genetic origins and parental expectations mirroring the donor's . Such concerns extend to violations of human dignity, with critics invoking "playing " by engineering , potentially commodifying and eroding natural familial bonds. Safety data from mammalian underscores these issues, with at least 95% of attempts failing via miscarriages, stillbirths, or severe anomalies like large , far exceeding IVF's historical hurdles. International bodies have reflected this opposition through non-binding measures, such as the Declaration on Human Cloning adopted on March 8, 2005, which urged states to prohibit all forms of incompatible with human dignity and life protection, passing 84-34 with 37 abstentions amid divisions over scope. Truth-seeking evaluation reveals scant human data due to absence of verified successes—claims like those from in 2002 remain unsubstantiated—while animal precedents indicate causal pathways for epigenetic errors and imprinting defects amenable to mitigation via protocol optimizations observed in post-2000s . However, without empirical human trials, assertions of safety parity with IVF lack substantiation, prioritizing caution given the technique's intrinsic vulnerabilities over speculative benefits.

Perspectives on Therapeutic Applications

Advocates for therapeutic applications of (SCNT) emphasize its potential to generate patient-specific embryonic s, which are genetically identical to the donor and thus minimize risks of immune rejection in regenerative therapies. This approach circumvents barriers that plague allogeneic transplants, enabling targeted treatments for conditions like or without lifelong immunosuppression. The has endorsed such research, distinguishing it from reproductive cloning by prioritizing therapeutic outcomes over embryo implantation, arguing that the empirical promise of disease-specific models and tissue repair justifies proceeding under strict oversight. Opponents contend that therapeutic SCNT inherently requires creating and destructing human embryos to harvest cells, conferring to early and violating principles of human dignity regardless of non-implantation intent. This process invites concerns, where technical mastery for could erode barriers to reproductive or commodify embryonic life, a amplified in sources wary of unchecked biotechnological expansion. Such arguments often highlight that abstract ethical prohibitions on embryo manipulation persist, even if patient-matched cells offer tangible medical gains, prioritizing intrinsic value over consequentialist benefits. In (), a variant of approved in the UK in for preventing mtDNA disease transmission, empirical outcomes demonstrate feasibility: initial clinical cases yielded healthy infants free of maternal mitochondrial disorders, with no observed carryover of diseased mitochondria beyond detection thresholds. These results substantiate claims that targeted germline interventions can avert severe, maternally inherited pathologies—such as , which claims 20-30% of affected infants before age five—outweighing speculative dignity-based objections when causal evidence shows preserved integrity and disease mitigation. Proponents, including panels, assert that for at-risk families, MRT's verified in averting heritable harm trumps broader fears of "three-parent" identities or unintended genetic alterations, grounded in observed clinical data rather than precautionary stasis.

Regulatory Responses and Innovation Impacts

In the United States, federal law does not prohibit therapeutic nuclear transfer, but the Dickey-Wicker Amendment, enacted in 1996 and annually renewed via appropriations riders, bars federal funding for research that destroys human embryos, effectively limiting public support for (SCNT) applications involving embryo creation. The (FDA) claims regulatory authority over (MRT), a form of nuclear transfer to prevent transmission, classifying it under oversight of human cells and tissues for implantation. However, a 2018 FDA advisory highlighted legal barriers, noting that MRT's embryo manipulation falls under embryo research restrictions, preventing approval of applications for clinical use and stalling progress despite technical feasibility demonstrated in preclinical models. State-level regulations vary, with at least 13 states, including and , imposing bans or funding prohibitions on therapeutic cloning as of 2023, creating a patchwork that complicates interstate research collaboration. Internationally, the enforces strict limits through the 2001 Clinical Trials Directive and national implementations, prohibiting reproductive via the Charter of Fundamental Rights while restricting therapeutic nuclear transfer; the does not fund embryo-destructive research, and 19 member states had banned human outright by 1998 under protocols, with ongoing enforcement prioritizing ethical caution over empirical advancement. In contrast, maintains a permissive stance for research on animal and therapeutic nuclear transfer, with regulations under the 2003 biosafety laws allowing SCNT for non-reproductive purposes; this framework supported milestones like the 2018 of via SCNT and subsequent 2020s expansions in chimeric research, positioning ahead in applied technologies amid a U.S.- biotech competition where Beijing's state-backed investments outpace Western counterparts constrained by funding caps. 's export controls on human cell technologies, updated in 2023, reflect strategic retention of innovations rather than outright bans, enabling domestic progress in areas like disease modeling. These regulatory disparities have demonstrably hindered in restrictive jurisdictions, as evidenced by the diversion of resources from R&D to —U.S. biotech firms report up to 20% of innovation budgets allocated to regulatory navigation, per 2011 analyses extrapolated to contexts—delaying therapeutic timelines by years compared to less encumbered programs. Empirical outcomes underscore causal effects: U.K. approval of in 2015 enabled clinical pathways absent in the U.S., while U.S. funding bans since 1996 have suppressed SCNT-derived yields, with private sector outputs lagging 's state-driven animal efficiencies by factors of 5-10 in reconstruction rates as of 2020 data. Overly precautionary frameworks, prioritizing hypothetical risks over iterative empirical refinement, have thus favored incremental progress in permissive environments, where regulatory flexibility correlates with higher patent filings in nuclear transfer variants— filing over 1,500 biotech-related patents annually by 2023 versus U.S. cloning-specific filings under 200.

Recent Developments

Efficiency Improvements (2020s)

In 2025, researchers demonstrated significant efficiency gains in (SCNT) by targeting both pre- and post-implantation epigenetic barriers in mice, achieving a full-term developmental rate of approximately 30% through combined strategies including overexpression of Kdm4d and Kdm5b demethylases, treatment with the (TSA), and tetraploid complementation. These interventions addressed persistent epigenetic memory from donor cells, which typically restricts cloned viability beyond early stages. Chemical reprogramming agents have further contributed to efficiency boosts, with TSA and similar histone-modifying compounds enhancing nuclear remodeling and gene activation in SCNT embryos, yielding formation rates exceeding 20% in optimized mouse protocols when integrated with genetic manipulations. Such approaches mitigate incomplete by facilitating decondensation and zygotic activation, outperforming traditional SCNT without additives. Advances in interspecies SCNT have also tackled cross-species incompatibilities, enabling derivation of human-like pluripotent s from or s with human nuclei, with meta-analyses indicating improved rates up to 10-15% in select protocols by refining oocyte selection and epigenetic synchronization. These developments circumvent ethical constraints on human oocytes while highlighting residual barriers like mitochondrial-nuclear mismatches, which ongoing refinements aim to resolve for scalable production.

Novel Applications in Infertility and Genetics

In September 2025, researchers at (OHSU) reported the generation of functional human egg-like cells from adult skin cells using (SCNT), a technique that reprograms nuclei within enucleated donor oocytes to produce haploid via induced mitomeiosis. This method yielded 82 early-stage oocyte-like structures capable of supporting fertilization, offering potential for individuals, including postmenopausal women and same-sex male couples, to produce genetically related offspring without relying on natural production. The approach leverages the cytoplasmic environment of donor oocytes to overcome epigenetic barriers in , though clinical application remains preclinical due to efficiency limitations around 1-2% success in maturation. SCNT has been combined with CRISPR-Cas9 to generate embryos corrected for monogenic disorders, where donor cells are first edited to repair mutations before nuclear transfer into enucleated oocytes. In porcine models, this pipeline achieved targeted corrections in genes like those for homologs, yielding viable blastocysts with edited nuclear genomes and minimal off-target effects, as verified by whole-genome sequencing. Similar integrations in canine SCNT produced genome-edited embryos targeting Parkinson's-related DJ-1 mutations, demonstrating 10-20% editing efficiency post-transfer. These 2020s advancements provide a foundation for human applications in preventing transmission of heritable conditions like , bypassing direct editing constraints. Pronuclear transfer, a variant of nuclear transfer, has enhanced the developmental viability of gametogenesis (IVG)-derived embryos by mitigating cytoplasmic deficiencies in lab-grown s. In 2024 mouse studies, pronuclei from zygotes formed by IVG oocytes and were transferred into enucleated metaphase II oocytes, rescuing formation rates from under 10% to over 50% and enabling live births upon , with no detectable chromosomal abnormalities via genetic analysis. This 2025-explored strategy addresses IVG challenges like impaired mitochondrial function and epigenetic maturation, potentially enabling human applications for production from induced pluripotent stem cells in cases of absolute or depletion.

Future Prospects

Potential for Human Therapeutics

Somatic cell nuclear transfer (SCNT) offers a pathway to derive patient-specific embryonic stem cells (ntESCs) with enhanced genetic fidelity for regenerative applications. Unlike induced pluripotent stem cells (iPSCs), which accumulate reprogramming-induced mutations at rates up to 10-20 per in mouse models, SCNT-derived ESCs from syngeneic donors show significantly lower loads, as evidenced by revealing fewer single nucleotide variants and indels. This reduced mutational burden from the oocyte's native machinery, which achieves more deterministic epigenetic erasure in approximately 24 hours compared to the prolonged, error-prone overexpression in iPSC generation. Consequently, ntESCs enable scalable into organoids—three-dimensional models—for disease modeling and drug screening, while minimizing risks of oncogenic transformations observed in iPSC lines. Mitochondrial replacement therapy (MRT), utilizing pronuclear or spindle transfer variants of , could extend beyond rare mtDNA disorders affecting 1 in 5,000 births to address mitochondrial dysfunction in prevalent conditions like or neurodegenerative diseases, where impaired efficiency contributes to cellular energy deficits. Initial approvals in 2015 targeted inherited syndromes, but preclinical data suggest compatibility with broader applications, such as enhancing viability in age-related impacting over 10% of women over 40. Empirical trials remain essential to quantify carryover mtDNA risks below 2% and long-term phenotypic outcomes, as current evidence derives primarily from animal models and limited studies. NT's core mechanism—oocyte-mediated —elucidates causal pathways for reversing age-associated epigenetic drift, informing partial strategies that restore youthful without inducing pluripotency. In human fibroblasts, transient exposure to factors mimicking NT's cytoplasmic cues ameliorates hallmarks, including nucleocytoplasmic compartmentalization defects and transcriptomic aging signatures, as quantified by reduced accumulation and improved nucleolar function. These insights, derived from SCNT's totipotency induction, underpin emerging anti-aging therapeutics that target Yamanaka factor subsets to extend cellular lifespan by 20-50% , potentially scalable to systemic rejuvenation via transient delivery. Validation human trials is pending, contingent on resolving delivery efficiency and off-target effects observed in partial models.

Broader Scientific and Ethical Implications

Nuclear transfer techniques, particularly (SCNT), reveal fundamental limitations in reductionist models of by demonstrating that genomic content alone cannot dictate organismal formation; instead, reprogramming hinges on oocyte-derived cytoplasmic factors that actively remodel nuclear , such as and modifications, to restore totipotency. This process highlights causal dependencies on non-genetic elements, including mitochondrial compatibility and nucleocytoplasmic interactions, which persist as barriers in interspecies applications and underscore the holistic nature of embryogenesis over purely informational genetic paradigms. Such insights extend to , where SCNT-derived knowledge of forced has informed protocols for generating patient-specific stem cells and exploring cellular assembly, potentially enabling engineered tissues or models of rare diseases without reliance on embryonic destruction. However, incomplete often yields aberrant , as evidenced by persistent transcriptional errors in cloned embryos, emphasizing the need for empirical validation of these mechanisms before scaling to synthetic constructs. Ethically, absolutist opposition to SCNT—rooted in concerns over commodifying and exacerbating identity crises in , as articulated in reports deeming reproductive incompatible with dignity—can constrain causal inquiries into failures, yet documented risks like 95-99% embryonic and elevated incidence of defects (e.g., large offspring syndrome) in survivors mandate precautionary verification to avoid unsubstantiated harms. While therapeutic applications promise organ regeneration, sources advocating unrestricted progress overlook systemic biases in discourse favoring innovation over evidenced safety thresholds; balanced advancement requires prioritizing data on long-term viability over ideological bans. Future integration into society depends on efficiency thresholds: SCNT's current 1-5% live birth rate pales against IVF's approximately 40%, confining it to experimental niches, but epigenetic interventions (e.g., METTL3 overexpression boosting rates) suggest potential convergence, enabling routine use in therapeutics if risks subside, or marginalization otherwise.

References

  1. [1]
    Somatic cell nuclear transfer: origins, the present position and future ...
    'Nuclear transfer' involves the transfer of the nucleus of a donor cell into an oocyte or early embryo from which the chromosomes have been removed.
  2. [2]
    Viable offspring derived from fetal and adult mammalian cells - Nature
    Feb 27, 1997 · We now report the birth of live lambs from three new cell populations established from adult mammary gland, fetus and embryo.
  3. [3]
    After Dolly The uses and misuses of human cloning - PMC
    Feb 1, 2007 · In the ten years since the production of Dolly, nuclear transfer has been successfully applied to a range of mammalian species for the ...
  4. [4]
    Cloning animals by somatic cell nuclear transfer – biological factors
    Somatic cell cloning (cloning or nuclear transfer) is a technique in which the nucleus (DNA) of a somatic cell is transferred into an enucleated metaphase-II ...
  5. [5]
    Ethical aspects of nuclear and mitochondrial DNA transfer - PMC - NIH
    This article analyzes somatic cell nuclear transfer (cloning) and mitochondrial DNA transfer techniques, in both reproductive and therapeutic applications.
  6. [6]
    Somatic cell nuclear transfer: origins, the present position and future ...
    Oct 19, 2015 · First, Dolly was the only adult clone and she was different from all other sheep in so many ways that there were no appropriate controls. She ...
  7. [7]
    Somatic Cell Nuclear Transfer in Mammals (1938-2013)
    Nov 4, 2014 · The result of the experiment was Dolly the sheep. Dolly was the first mammal cloned from a fully differentiated adult cell. The main ...Missing: paper | Show results with:paper
  8. [8]
    Hans Spemann (1869-1941) | Embryo Project Encyclopedia
    Jun 15, 2010 · ... Spemann's pondering about nuclear transplantation helped pave the way for the first nuclear-transfer experiments in 1952. By then Spemann ...Missing: date | Show results with:date
  9. [9]
    Transplantation of living nuclei from blastula cells into enucleated ...
    Transplantation of living nuclei from blastula cells into enucleated frogs' eggs *. Robert Briggs and Thomas J. KingAuthors Info & Affiliations. May 15, 1952.
  10. [10]
    The first half-century of nuclear transplantation - PMC - NIH
    Briggs and King were the first to open the way to a direct test of the genetic equivalence of somatic cell nuclei in development and cell differentiation.
  11. [11]
    [PDF] Sir John B. Gurdon - Nobel Lecture: The Egg and the Nucleus
    Design of a somatic cell nuclear transfer experiment using unfertilised eggs as first designed by Briggs and King (1952) for Rana pipiens and as used ...Missing: 1920s- | Show results with:1920s-
  12. [12]
    Nuclear transplantation: lessons from frogs and mice - ScienceDirect
    Briggs and King noted that cloned frog embryos derived from endoderm nuclei showed normal development of endodermal derivatives but abnormal development of ...
  13. [13]
    Sheep: The First Large Animal Model in Nuclear Transfer Research
    We shall instead provide an overview on the work done specifically on sheep and the value of this work on the greater nuclear transfer landscape.
  14. [14]
  15. [15]
    The History of Cloning - Learn Genetics Utah
    This experiment showed that it was possible to clone a mammal by nuclear transfer—and that the clone could fully develop. ... controversies over human cloning and ...
  16. [16]
    "Sheep Cloned by Nuclear Transfer from a Cultured Cell Line" (1996 ...
    Sep 19, 2014 · To do so, they used electrical fusion methods developed by Steen Willadsen at the British Agricultural Research Council's Institute of Animal ...
  17. [17]
    V: Dolly the sheep - the first cloned mammal and a public icon for ...
    Attribution: Wilmut and colleagues (Roslin Institute, UoE), undertook somatic cell nuclear transfer and used it to perform the first successful cloning of an ...
  18. [18]
    Dolly the sheep becomes first successfully cloned mammal | HISTORY
    Dolly's birth was announced publicly in February 1997 to a storm of controversy. ... Over the course of her short life, Dolly was mated to a male sheep named ...
  19. [19]
    20 Years After Dolly the Sheep, What Have We Learned About ...
    Feb 22, 2017 · Today marks the 20th anniversary of the announcement of Dolly the sheep, the first mammal cloned from an adult cell.
  20. [20]
    Scientists In Hawaii Report First Reproducible Cloning Of Mammals ...
    Jul 23, 1998 · Wakayama, the study's lead author. The donor nuclei came from cumulus cells, which surround developing eggs within the ovaries of female mice.
  21. [21]
    The many problems of somatic cell nuclear transfer in reproductive ...
    Sep 1, 2022 · Dolly was the only viable infant of 277 couplets created with mammary epithelium cells [3]. In 1998, the 'Honolulu technique' was developed [9], ...
  22. [22]
    Epigenetic Reprogramming During Somatic Cell Nuclear Transfer
    Mar 17, 2020 · Although SCNT has been successfully used to clone many species of mammals with significant improvements in cloning efficiency in more than 20 ...
  23. [23]
    CVM Researchers First to Clone Cat | VMBS News
    Feb 14, 2002 · Researchers at the College of Veterinary Medicine at Texas A&M University have cloned a cat. A kitten, named “cc,” was born to “Allie” a surrogate mother.
  24. [24]
    Cloned Endangered Species Is Born, Dies | Science | AAAS
    Noah, an endangered gaur, lived just 2 days. The first clone of an endangered species died Wednesday, two days after its birth on 8 January.
  25. [25]
    Timeline of a controversy : Nature News
    Dec 19, 2005 · Woo Suk Hwang from Seoul National University in South Korea and colleagues announced that they have cloned 30 human embryos and harvested stem ...
  26. [26]
    Hwang Indicted for Fraud, Embezzlement | Science | AAAS
    Once-famed, now disgraced stem cell pioneer Woo Suk Hwang was indicted today on charges of fraud, embezzlement, and violations of a bioethics law.
  27. [27]
    Improving Cloning Efficiency | Harvard Medical School
    Nov 6, 2014 · While researchers have accomplished SCNT in many animal species, it could work better than it does now. It took the scientists who cloned Dolly ...
  28. [28]
    Recent advancements in cloning by somatic cell nuclear transfer
    Jan 5, 2013 · Although how HDACi treatment improves cloning efficiency remains unknown, it is thought that it can induce hyperacetylation of the core histones ...<|control11|><|separator|>
  29. [29]
    Strategies to Improve the Efficiency of Somatic Cell Nuclear Transfer
    We review the recent approaches for technical SCNT improvement and ameliorating epigenetic modifications in donor cells, oocytes, and cloned embryos.
  30. [30]
    Somatic Cell Nuclear Transfer Reprogramming - NIH
    Oct 4, 2019 · Totipotency is defined as the ability of a cell to give rise to all cell types of an entire organism (Lu and Zhang, 2015). In normal mammalian ...
  31. [31]
    Handmade cloning: recent advances, potential and pitfalls
    Oct 15, 2015 · Handmade cloning (HMC) is the most awaited, simple and micromanipulator-free version of somatic cell nuclear transfer (SCNT).Missing: variant | Show results with:variant
  32. [32]
    Optimization of handmade cloning enhances pregnancy rates and ...
    Apr 29, 2025 · Dolly became the first mammal cloned from an adult cell using somatic cell nuclear transfer (SCNT), a process now widely known as cloning.
  33. [33]
    Mitochondrial Donation and Preimplantation Genetic Testing for ...
    Jul 16, 2025 · Mitochondrial donation by pronuclear transfer involves transplantation of nuclear genome from a fertilized egg from the affected woman to an ...
  34. [34]
    Mitochondrial replacement techniques under the spotlight - Nature
    Jul 1, 2014 · One approach that is currently under investigation is mitochondrial replacement by pronuclear transfer (PNT), in which the parental pronuclei ...
  35. [35]
    Pronuclear transfer in human embryos to prevent transmission ... - NIH
    Our studies show that in human zygotes, pronuclear transfer has the potential to “treat” human mtDNA disease at a genetic level. The recent development of ...
  36. [36]
    U.K. Parliament approves controversial three-parent mitochondrial ...
    Feb 3, 2015 · U.K. Parliament approves controversial three-parent mitochondrial gene therapy. Experimental technique, designed to prevent inherited disease, ...
  37. [37]
    Mitochondrial donation treatment - HFEA
    Two techniques for mitochondrial donation have been developed and approved by Parliament: maternal spindle transfer (MST) and pronuclear transfer (PNT). In both ...
  38. [38]
    Eight babies born after Mitochondrial donation - Newcastle University
    Jul 16, 2025 · The babies, four girls and four boys, including one set of identical twins, were born to seven women at high risk of transmitting serious ...
  39. [39]
    Mitochondrial Donation and PGT to Reduce Risk of ... - NIH
    Jul 31, 2025 · Mitochondrial donation through pronuclear transfer is compatible with human embryo viability. An integrated programme of pronuclear transfer and ...Pronuclear Transfer, Embryo... · Embryo Transfer And... · Heteroplasmy After...<|separator|>
  40. [40]
    Interspecies Nuclear Transfer: Implications for Embryonic Stem Cell ...
    Nov 15, 2007 · This review focuses on the challenges and opportunities presented by the formidable task of overcoming biological differences among species.
  41. [41]
    Reprogramming of human somatic cells using human and animal ...
    Here we compare the reprogramming of human somatic nuclei using oocytes obtained from animal and human sources.
  42. [42]
    Embryonic stem cells generated by nuclear transfer of human ...
    Aug 1, 2003 · Here we have derived embryonic stem cells by the transfer of human somatic nuclei into rabbit oocytes.<|separator|>
  43. [43]
    Interspecies Somatic Cell Nuclear Transfer - PubMed Central - NIH
    iSCNT for cloning animals works only for species that can interbreed, and experiments with taxonomically distant species have not been successful.
  44. [44]
    The Complexities of Interspecies Somatic Cell Nuclear Transfer
    Apr 2, 2025 · Mitonuclear incompatibility in iSCNT embryos: (A) Following iSCNT, mitonuclear communication occurs between donor nuclear DNA, donor-derived ...
  45. [45]
    The Complexities of Interspecies Somatic Cell Nuclear Transfer
    Apr 2, 2025 · We highlight recent findings deepening the understanding of interspecies barriers in iSCNT, emphasizing their interconnected complexities.
  46. [46]
    Current status of interspecies somatic cell nuclear transfer and meta ...
    Apr 3, 2024 · Interspecies somatic cell nuclear transfer (iSCNT) has the capacity to rescue endangered species, ethically produce human embryonic stem cells, ...
  47. [47]
    Antimitotic treatments for chemically assisted oocyte enucleation in ...
    Therefore, demecolcine- and nocodazole-assisted enucleation appears as an efficient alternative to mechanical enucleation, which can simplify nuclear transfer ...
  48. [48]
    Chemically Assisted Enucleation Results in Higher G6PD ...
    The hypothesis of our study was that the use of cytoplasts produced by chemically assisted enucleation (EN) would improve nuclear reprogramming in nuclear ...
  49. [49]
    Effects of Preactivation of Ooplasts or Synchronization of Blastomere ...
    Preactivation of ooplasts before nuclear transfer (NT) raises the rate of preimplantation development from 15% to 56%, which remains elevated in the next series ...
  50. [50]
    Effect of ooplast activation on the development of oocytes following ...
    We assessed the effect of ooplast (enucleated oocytes) activation prior to receiving a donor nucleus on the development of nucleus transferred oocytes in ...
  51. [51]
    Early and delayed aspects of nuclear reprogramming during cloning
    Jan 9, 2012 · By 30 min after transfer, nuclear envelope breakdown has occurred, and the chromosomes are condensed and stain strongly for H1FOO. By 60 min ...
  52. [52]
    Nuclear Remodeling in Bovine Somatic Cell Nuclear Transfer ...
    Nov 25, 2010 · Chromosome condensation and nuclear envelope breakdown are mediated by MPF activity, which needs be high in recipient oocytes to promote ...
  53. [53]
    [PDF] EMBRYONIC GENOME ACTIVATION - IMR Press
    For other species, including the rabbit, cow, rhesus macaque, and human, for which the major genome activation event occurs around the 4-8 cell stage, recent ...
  54. [54]
    Reprogramming within hours following nuclear transfer into mouse ...
    Oct 4, 2011 · This arrest was associated with a failure to activate transcription in the transferred somatic genome. In contrast to human zygotes, mouse ...
  55. [55]
    Kinetics of Cell Cycle and Metabolic Progression as Determinants of ...
    Time-lapse records were analyzed for errors in cell divisions leading ... nuclear reprogramming in somatic cell nuclear transfer? BioEssays : news and ...
  56. [56]
    Abnormal chromosome segregation at early cleavage is a major ...
    Apr 1, 2012 · Recent analyses of SCNT embryos have revealed many abnormalities caused by incomplete epigenetic reprogramming of the donor nucleus as being ...
  57. [57]
    Lessons Learned from Somatic Cell Nuclear Transfer - PMC
    This represents the first case to report the reprogramming of a somatic cell to a totipotent state via an enucleated egg.
  58. [58]
    Efficient Somatic Cell Nuclear Transfer by Overcoming Both Pre
    Jul 8, 2025 · Epigenetic barriers inherited from somatic cells impede reprogramming efficiency and lead to low SCNT embryo development rates. Recent studies ...
  59. [59]
    Epigenetic Reprogramming During Somatic Cell Nuclear Transfer
    For DNA methylation, cloned embryos demonstrate delayed DNA demethylation and incomplete DNA remethylation of genome (the data shown here represent DNA ...
  60. [60]
    Incomplete methylation reprogramming in SCNT embryos - PubMed
    A new genome-wide study shows that epigenetic reprogramming in SCNT embryos does not fully recapitulate the natural DNA demethylation events occurring at ...
  61. [61]
    Epigenetic manipulation to improve mouse SCNT embryonic ...
    DNA methylation may be an epigenetic barrier for somatic cell nuclear transfer post-implantation development. In post-implantation fertilized embryos, DNA ...
  62. [62]
    H3K9me3 and H3K27me3 are epigenetic barriers to somatic cell ...
    Our findings demonstrate that H3K9me3 and H3K27me3 inhibit the expression of genes essential for the development and preimplantation of NT embryos.
  63. [63]
    Loss of H3K27me3 Imprinting in Somatic Cell Nuclear Transfer ...
    Jul 19, 2018 · Recent studies have identified H3K9me3 in donor cells and abnormal Xist activation as epigenetic barriers that impede SCNT. Here we overcome ...
  64. [64]
    Loss of H3K27me3 imprinting in the Sfmbt2 miRNA cluster causes ...
    May 1, 2020 · Thus, we identify loss of H3K27me3 imprinting as an epigenetic error that compromises embryo development following SCNT. Similar content being ...
  65. [65]
    Overcoming Intrinsic H3K27me3 Imprinting Barriers Improves Post ...
    Jun 18, 2020 · These results show that lack of H3K27me3 imprinting in somatic cells is an epigenetic barrier that impedes post-implantation devel- opment of ...
  66. [66]
    X chromosome reactivation and regulation in cloned embryos
    We conclude that, although SCNT embryos can reactivate, count, and inactivate X chromosomes, they are not able to regulate XCI consistently.
  67. [67]
    X Chromosome Reactivation in Reprogramming and in Development
    Nov 11, 2015 · Impeding Xist expression from the active X chromosome improves mouse somatic cell nuclear transfer. Science. 2010;330:496–499. doi: 10.1126 ...
  68. [68]
    Enhancing somatic nuclear reprogramming by Oct4 gain-of-function ...
    Oct 4, 2024 · Our results show that supplemental Oct4 facilitates oocyte-mediated reprogramming only during the first cleavages, implying that the higher Oct4 ...
  69. [69]
    Characterization of somatic cell nuclear reprogramming by oocytes ...
    When transplanted into Xenopus oocytes, the nuclei of mammalian somatic cells are reprogrammed to express stem cell genes such as Oct4, Nanog, and Sox2.
  70. [70]
    Epigenetic manipulation to improve mouse SCNT embryonic ...
    Aug 30, 2022 · However, low efficiency hampers the application of SCNT and its extension. The standard SCNT efficiency is only 1%–5%, which results in a ...Missing: live | Show results with:live
  71. [71]
    Efficient Somatic Cell Nuclear Transfer by Overcoming Both Pre ...
    Jul 8, 2025 · Epigenetic barriers inherited from somatic cells impede reprogramming efficiency and lead to low SCNT embryo development rates. Recent studies ...
  72. [72]
    Embryonic Development following Somatic Cell Nuclear Transfer ...
    Oct 30, 2014 · Our study thus identifies H3K9me3 as a critical epigenetic barrier in SCNT-mediated reprogramming and provides a promising approach for ...Missing: live | Show results with:live
  73. [73]
    Cloning of Domestic Animals - Reproductive System
    This technique, known as somatic cell nuclear transfer (SCNT), enables the production of genetically identical clones of the donor.
  74. [74]
    Scientific opinion on the impact of somatic cell nuclear transfer ...
    May 2, 2024 · This document has been drafted to develop a scientific opinion concerning the impact of somatic cell nuclear transfer (SCNT) technologies, primarily in cattle ...
  75. [75]
    Semen parameters and fertility potency of a cloned water buffalo ...
    Aug 21, 2020 · These results showed that semen from a cloned bull derived from SedECs is equivalent to semen from its donor bull and bulls cloned from SkdFCs.
  76. [76]
    Successful cloning of a superior buffalo bull | Scientific Reports
    Aug 6, 2019 · Following artificial insemination with frozen semen doses, the conception rate (55%) of cloned bull semen was comparable to non-cloned bulls, ...
  77. [77]
    NDRI set to provide cloned animal semen to farmers - The Tribune
    Mar 6, 2025 · In November 2021, scientists achieved another milestone when 12 calves were born using semen from cloned buffalo bulls, demonstrating that the ...
  78. [78]
    Evaluation of postnatal growth, hematology, telomere length and ...
    Jan 1, 2024 · The bulls were used for semen production after being screened for testicular growth and training. ... Additionally, it was found that cloned bulls ...
  79. [79]
    Stem cells: What they are and what they do - Mayo Clinic
    Therapeutic cloning, also called somatic cell nuclear transfer, is a way to create versatile stem cells independent of fertilized eggs. In this technique, the ...
  80. [80]
    Human Somatic Cell Nuclear Transfer Using Adult Cells
    Jun 5, 2014 · In this study, we describe the application of a recently developed methodology for the generation of human ESCs via SCNT using dermal fibroblasts from 35- and ...
  81. [81]
    Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer: A ...
    Sep 10, 2016 · This review describes recently developed human ESCs from somatic cell nuclear transfer blastocysts and discusses their advantages and ...
  82. [82]
    Therapeutic Cloning: Potential, Challenges, and Ethical Considera
    Since the stem cells generated through therapeutic cloning are genetically identical to the donor, they are less likely to be rejected by the immune system when ...
  83. [83]
    Stem cell therapies and benefaction of somatic cell nuclear transfer ...
    May 12, 2021 · The stem cells generated by SCNT and induced pluripotency are promising tools for personalized requirements of regenerative medicine, ...
  84. [84]
    Generating Cloned Goats by Somatic Cell Nuclear Transfer ... - MDPI
    Cloned goats are generated using somatic cell nuclear transfer (SCNT), a rapidly developing cloning strategy, to create genetically engineered animals.<|separator|>
  85. [85]
    Efficient production of multi-modified pigs for xenotransplantation by ...
    Jun 29, 2016 · Serial nuclear transfer was key to the strategy we employed as it enabled sequential transgene addition and gene editing steps to generate pigs ...
  86. [86]
    Creating genetically modified pigs by using nuclear transfer - PMC
    Nuclear transfer would speed up the expansion of a successful transgenic line by using skin cells of the transgenic pigs to make more clones. Ear skin ...
  87. [87]
    Cutting edge of genetically modified pigs targeting complement ...
    Apr 3, 2024 · Pigs are optimal donors for xenotransplantation due to their genetic, physiological, and anatomical similarities to humans, alongside their ...
  88. [88]
    In a conservation first, a cloned ferret could help save her species
    Jan 13, 2022 · By cloning a black-footed ferret that died in 1988, biologists hope to add greater genetic diversity to the existing population of this ...
  89. [89]
    Genetic Research Boosts Black-footed Ferret Conservation Efforts
    Feb 18, 2021 · “The ability to utilize our proven Somatic Cell Nuclear Technology to enable the cloning of such an ecologically important species is a great ...
  90. [90]
    2 black-footed ferret babies born to cloned mom for the first time
    Nov 11, 2024 · Antonia, a cloned black-footed ferret at the Smithsonian's National Zoo and Conservation Biology Institute, has produced two healthy offspring.
  91. [91]
    Gene Pool Enrichment of the Black-Footed Ferret - Oxford Academic
    Aug 24, 2015 · Interspecies somatic cell nuclear transfer (iSCNT) could benefit recovery programs of critically endangered species but must be weighed with ...<|separator|>
  92. [92]
    First U.K. Children Are Born Using DNA from Three 'Parents'
    May 12, 2023 · In 2016, a US doctor announced that he had used MRT successfully to prevent mitochondrial disease in a baby, in a procedure conducted in Mexico.
  93. [93]
    Induction of experimental cell division to generate cells with reduced ...
    Sep 30, 2025 · Somatic cell nuclear transfer (SCNT) enables the direct reprogramming of somatic cells into functional oocytes, albeit with a diploid genome ...
  94. [94]
    OHSU researchers develop functional eggs from human skin cells
    Sep 30, 2025 · The technique involves transplanting a skin cell nucleus into a donor egg stripped of its nucleus.Missing: 2024 | Show results with:2024
  95. [95]
    Mitochondrial Donation in a Reproductive Care Pathway for mtDNA ...
    Jul 16, 2025 · A reproductive care pathway was implemented to provide women carrying pathogenic mtDNA variants with reproductive options.Results · Reproductive Care Pathway · Assessment Of Mtdna Variant...
  96. [96]
    Human germline nuclear transfer to overcome mitochondrial ...
    Jan 22, 2022 · NT has been applied to minimize transmission risk of mitochondrial DNA (mtDNA) diseases. NT has also been proposed for treating infertility.
  97. [97]
    25th ANNIVERSARY OF CLONING BY SOMATIC-CELL NUCLEAR ...
    The birth and adult development of 'Dolly' the sheep, the first mammal produced by the transfer of a terminally differentiated cell nucleus into an egg, ...
  98. [98]
    Lessons Learned from Somatic Cell Nuclear Transfer - MDPI
    As early as the 1980s, artificial chemical induction treatments were developed to mimic the biochemical processes activated by natural sperm stimulation [69].
  99. [99]
    Nuclear Donor Cell Lines Considerably Influence Cloning Efficiency ...
    Jan 16, 2013 · The cloning efficiency was significantly higher in group F5 than those in group F1, F2, F3 and F4 (9.3% vs 4.1%, 1.2%, 2.0% and 5.0%, ...
  100. [100]
    Towards Practical Conservation Cloning: Understanding the ...
    Although the number of wildlife clones pales in comparison to the thousands of cloned animals produced for commercial and biomedical research purposes, the ...
  101. [101]
    Swine clones: potential application for animal production and ... - NIH
    Cloning by SCNT is mainly used for commercial purposes to produce cattle and horses in countries such as the United States, Argentina, Brazil, China, and ...
  102. [102]
    Reprogramming and Somatic Cell Nuclear Transfer (SCNT)
    Somatic Cell Nuclear Transfer (SCNT) aims to generate isogenic ESCs from a patient's own cells, a concept called 'therapeutic cloning'.
  103. [103]
    Reprogramming to recover youthful epigenetic information and ...
    These data indicate that mammalian tissues retain a record of youthful epigenetic information—encoded in part by DNA methylation—that can be accessed to improve ...
  104. [104]
    Age reprogramming and epigenetic rejuvenation
    Dec 20, 2018 · Age reprogramming represents a novel method for generating patient-specific tissues for transplantation. It bypasses the de-differentiation/redifferentiation ...
  105. [105]
    Nuclear reprogramming and pluripotency - PubMed - NIH
    Jun 29, 2006 · The cloning of mammals from differentiated donor cells has refuted the old dogma that development is an irreversible process.Missing: disproved | Show results with:disproved
  106. [106]
    25th ANNIVERSARY OF CLONING BY SOMATIC-CELL NUCLEAR ...
    Jun 16, 2021 · This theory was refuted by the birth of Dolly, the first animal generated by nuclear transfer using an adult somatic cell as a nuclear donor.
  107. [107]
    Nearly a Century of Nuclear Transfer Research: Milestones ...
    Aug 6, 2025 · This review provides a comprehensive overview of the key milestones in its development, its practical applications, and the challenges it ...
  108. [108]
    Genomic insights into chromatin reprogramming to totipotency in ...
    Generation of a totipotent embryo involves chromatin reorganization and epigenetic reprogramming that alter DNA and histone modifications. Understanding ...
  109. [109]
    Somatic Cell Nuclear Transfer Reprogramming: Mechanisms and ...
    Oct 4, 2018 · Here, we summarize recent advances in SCNT technology and its potential applications for both reproductive and therapeutic cloning.Missing: handmade | Show results with:handmade
  110. [110]
    Will cloned animals suffer premature aging – The story at the end of ...
    [16] verified that telomere shortening is not a necessary outcome of the cloning process. It appears that the embryo has inherited ability to determine the ...Missing: debunked | Show results with:debunked
  111. [111]
    Telomere length is reset during early mammalian embryogenesis
    Telomere shortening limits the regenerative capacity of cells and is correlated with the onset of cancer, aging, and chronic diseases (8–12). The segregation of ...Missing: myth debunked
  112. [112]
    DNA- and telomere-damage does not limit lifespan - Aging-US
    Fifth, nuclear transfer and nuclear reprogramming both rule out DNA damage as a cause of aging.Missing: myth debunked
  113. [113]
    Factors Affecting the Development of Somatic Cell Nuclear Transfer ...
    However, the efficiency of somatic cell cloning has remained low, and applications have been limited. In this review, we discuss some of the factors that affect ...
  114. [114]
    Current state of the efficiency of sheep embryo production through ...
    Since the birth of Dolly, numerous studies have focused on improving the efficiency of SCNT in sheep, however, the overall efficiency remains low, typically ...
  115. [115]
    Chromosome microduplication in somatic cells decreases ... - Nature
    May 12, 2015 · Our results show that aneuploidy induced by somatic cell nuclear transfer technology is a key factor in the developmental failure of cloned human embryos and ...Results · Scnt Embryos And Primary... · Embryonic Chromosome...Missing: asynchronous | Show results with:asynchronous
  116. [116]
    Embryo development after SCNT. Oocytes were obtained by OPU ...
    We observed a higher blastocyst formation rate when in vivo matured oocytes (43.45 ± 2.07%) were used compared to in vitro matured oocytes (21.52 ± 1.74%). The ...
  117. [117]
    Cloned ferrets produced by somatic cell nuclear transfer
    Successful SCNT is highly dependent upon oocyte quality. To prepare donor oocytes for nuclear transfer (NT), we initially attempted to obtain in vivo matured ...
  118. [118]
    Inhibition of Wnt activity improves peri-implantation development of ...
    Aug 16, 2023 · Somatic cell nuclear transfer (SCNT) can reprogram differentiated somatic cells into totipotency. Although pre-implantation development of SCNT ...Inhibition Of Wnt Activity... · Results · Wnt Activity Persists Upon...<|separator|>
  119. [119]
    Strategies to Improve the Efficiency of Somatic Cell Nuclear Transfer
    Notably, CICT significantly increased the birth rate of cloned cat embryos when compared to that of SCNT (4.8% and 0.7%, respectively) [78]. In contrast, ...
  120. [120]
    Review: The Health of Somatic Cell Cloned Cattle and Their Offspring
    The cloning syndrome is a continuum with the consequences of abnormal reprograming manifest throughout gestation, the neo-natal period, and into adulthood ...
  121. [121]
    Review: Large offspring syndrome in ruminants - ScienceDirect.com
    However, an abnormal placenta alone does not explain other anatomic abnormalities observed in LOS and BWS such as body-wall defects, hemi hyperplasia (body ...
  122. [122]
    Dolly's arthritis dents faith in cloning - PMC - NIH
    Telomeres shorten with each cell division and are considered a marker of the ageing process. While arthritis is not uncommon in sheep, the typical age at onset ...
  123. [123]
    Healthy ageing of cloned sheep | Nature Communications
    Jul 26, 2016 · A relatively high proportion of clones also fail to successfully make the transition to extra-uterine life, some harbouring congenital defects, ...
  124. [124]
    Dolly the sheep died young. Her cloned sisters are going strong
    Jul 26, 2016 · (After developing a rare lung disease, Dolly died at age 6, less than half the lifespan her species can reach.) The other nine clones came from ...
  125. [125]
    Mitochondrial DNA transmission and confounding ... - NIH
    Mitochondrial heteroplasmy/exchange can affect developmental ability, health, and uniformity of SCNT offspring produced.
  126. [126]
    Mitochondria and the success of somatic cell nuclear transfer cloning
    The overall success of somatic cell nuclear transfer (SCNT) cloning is rather unsatisfactory, both in terms of efficacy and from an animal health and welfare ...
  127. [127]
    25th ANNIVERSARY OF CLONING BY SOMATIC-CELL NUCLEAR ...
    Jun 11, 2021 · SCNT (somatic cell nuclear transfer) has complemented the toolbox of ARTs offering yet another technique to reproduce animals in an unprecedented way.
  128. [128]
    Cloning horses by somatic cell nuclear transfer: Effects of oocyte ...
    Hence, as large numbers of oocytes are needed to produce a cloned foal, a major constraint of equine SCNT is the supply of oocytes [5].
  129. [129]
    Initiate Cloning - Viagen Pets
    The total cost of cat cloning is $50,000, also paid in two equal installments. The total cost of horse cloning is $85,000, also paid in two equal installments.
  130. [130]
    The $50,000 dog-cloning business is booming - New York Post
    Nov 14, 2024 · To clone a pet, tissue cells are harvested, cultured and frozen before or just after the animal dies. ViaGen charges $150 annually, on top ...
  131. [131]
    Thousands of People Are Cloning Their Dead Pets. This Is ... - WIRED
    Nov 4, 2024 · Testimonials from tomorrow's workforce. It had taken seven months and cost $50,000, but that cat was one of the first pets to be commercially ...
  132. [132]
    Molecular and functional resemblance of differentiated cells ... - PNAS
    Dec 4, 2017 · We conclude that human iPSCs are capable of replacing SCNT for generating differentiated cells for drug testing and disease modeling.
  133. [133]
    Induced pluripotent stem cells (iPSCs): molecular mechanisms of ...
    Apr 26, 2024 · iPSCs have been widely applied to model human development and diseases, perform drug screening, and develop cell therapies.<|separator|>
  134. [134]
    Advances in Pluripotent Stem Cells: History, Mechanisms ... - NIH
    Relative to other stem cell approaches, SCNT is unique in that it can generate an entire living body rather than sheets of cells, tissues, and pieces of organs ...
  135. [135]
    Cloning | Internet Encyclopedia of Philosophy
    One of the most predominate themes underlying arguments for reproductive cloning is an appeal to procreative liberty. Because cloning may provide the only way ...Types of Cloning · Arguments in Favor of... · Arguments Against...
  136. [136]
    Just another reproductive technology? The ethics of human ...
    A recently published meta‐analysis of papers investigating the risk of birth defects in infants born by IVF found, on average, a 30–40% greater risk of birth ...
  137. [137]
    Human Reproductive Cloning: Possible Psychological Consequences
    Jul 28, 2025 · However, adoption can pose risks, given the unknown backgrounds of the individuals relinquishing children for reasons of unwed marital status, ...
  138. [138]
    Reproductive Cloning Arguments Pro and Con
    Aug 3, 2021 · Arguments against cloning include it diminishing uniqueness and being unsafe. Arguments for include helping those with fertility issues and ...
  139. [139]
    GENERAL ASSEMBLY ADOPTS UNITED NATIONS DECLARATION ...
    Mar 8, 2005 · The United Nations Declaration on Human Cloning (document A/59/516/Add.1) was adopted by a recorded vote of 84 in favour to 34 against, with 37 ...
  140. [140]
    Cloning Fact Sheet - National Human Genome Research Institute
    Aug 15, 2020 · However, both reproductive and therapeutic cloning raise important ethical issues, especially as related to the potential use of these ...
  141. [141]
    Scientific and Medical Aspects of Human Reproductive Cloning - NCBI
    The collection of these eggs would bring with it the risk of ovarian hyperstimulation syndrome in donors, as with all in vitro fertilization (IVF). However, in ...
  142. [142]
    Pluripotent cells created by nuclear transfer can prompt immune ...
    Nov 20, 2014 · The promise of the SCNT method is that the nucleus of a patient's skin cell, for example, could be used to create pluripotent cells that might ...
  143. [143]
    American Medical Association approves stem cell research - PMC
    Somatic cell nuclear transfer, used for therapeutic cloning, produces "designer stem cells" that are unique to each patient. Because the patient's own cells ...Missing: position | Show results with:position
  144. [144]
    Therapeutic cloning: promises and issues - PMC - NIH
    Therapeutic cloning offers significant potential in regenerative medicine by circumventing immunorejection, and in the cure of genetic disorders.Missing: bottlenecks populations
  145. [145]
    Ethical questions in embryonic stem cell research - EuroGCT
    Arguments against using unused embryos​​ This is the beginning of a slippery slope, which may lead to dehumanising scenarios like embryo farms or cloned foetuses ...
  146. [146]
    Cloning - Stanford Encyclopedia of Philosophy
    Sep 17, 2008 · On this view, creating and killing embryos for stem cells is a serious moral wrong. It is impermissible, even if it could save many lives ( ...<|separator|>
  147. [147]
    Controversies concerning mitochondrial replacement therapy - PMC
    Research on mitochondrial replacement therapy (MRT) holds the promise of helping women who have, or are at risk of transmitting, mitochondrial disease.Objections To Mrt · Possible Biological Risks · Arguments In Favor Of Mrt
  148. [148]
    Scientific and Ethical Issues in Mitochondrial Donation - PMC
    In support of this, the Nuffield Council on Bioethics concluded that it would be ethical to use either MST or PNT in the clinical application of mitochondrial ...1. Introduction · Figure 2 · 2. The Use Of Human Embryos...
  149. [149]
    Clinical Investigations of Mitochondrial Replacement Techniques ...
    Feb 3, 2016 · Clinical investigations of mitochondrial replacement techniques are 'ethically permissible' if significant conditions are met, says new report.
  150. [150]
    Therapeutic Cloning and Genome Modification - FDA
    Mar 16, 2018 · Somatic Nuclear Transfer (SCNT) was successfully used in 1997 to create the cloned sheep Dolly. SCNT is a technique were the nucleus of a donor ...
  151. [151]
    Advisory on Legal Restrictions on the Use of Mitochondrial ... - FDA
    Mar 16, 2018 · FDA's oversight includes ensuring that human cells and tissues intended for transfer into a human recipient, including reproductive cells and ...
  152. [152]
    Appendix: State Laws on Human Cloning - The New Atlantis
    There are no federal laws regulating human cloning in the United States, with the exception of laws and policies restricting the federal government from ...
  153. [153]
    Prohibition of cloning human beings
    This report argues that any intervention seeking to clone human beings should be prohibited and subjected to penal sanctions.
  154. [154]
    Regulatory framework of human germline and heritable genome ...
    May 13, 2025 · China's existing regulatory framework for human genome editing has improved with several laws enacted and updated, but there are shortcomings.Missing: 2020s | Show results with:2020s
  155. [155]
    China Proposes to Prohibit Export of Certain Human Cell Cloning ...
    Feb 17, 2023 · The Proposed Catalogue adds 7, removes 32, and clarifies 36 technologies, placing a total of 139 technologies under export control.
  156. [156]
    [PDF] The Impact of Regulation on Innovation in the United States
    First, regulation places a compliance burden on firms, which can cause them to divert time and money from innovative activities to compliance efforts.<|control11|><|separator|>
  157. [157]
    Mitochondrial replacement therapy: the UK and US regulatory ...
    Nov 22, 2016 · In the USA, the use of MRT falls under the oversight of the US Food and Drug Administration (FDA), and its approval, which would require ...
  158. [158]
    China Expands Technology Export Controls - Global Trade Law Blog
    Sep 2, 2020 · New export regulations may require licenses from the Chinese government before researchers in China may share their technological advances with ...<|separator|>
  159. [159]
    Overcoming the H4K20me3 epigenetic barrier improves somatic cell ...
    Jun 15, 2023 · Overcoming the H4K20me3 epigenetic barrier improves somatic cell nuclear transfer reprogramming efficiency in mice. Zhihui Liu. Zhihui Liu. 1 ...
  160. [160]
    Somatic Cell Nuclear Transfer Followed by CRIPSR/Cas9 ... - MDPI
    In this article, we investigated for the first time a combination of somatic cell nuclear transfer (SCNT) and direct injection of CRISPR/Cas ribonucleoprotein ...
  161. [161]
    Generation of genome-edited dogs by somatic cell nuclear transfer
    Jul 13, 2022 · We successfully produced CRISPR-Cas9-mediated genome-edited dogs using the SCNT technology. We targeted DJ-1 in the canine genome and confirmed ...Missing: 2020s | Show results with:2020s
  162. [162]
    Pronuclear transfer rescues poor embryo development of in vitro ...
    Feb 7, 2024 · Genetic analysis and embryo transfer of the generated embryos were implemented to confirm the safety of the technique.
  163. [163]
    Mouse SCNT ESCs Have Lower Somatic Mutation Load Than ...
    Apr 8, 2014 · Exome sequencing of these lines indicates a significantly lower mutation load in SCNT ESCs than iPSCs of syngeneic background.
  164. [164]
    A highly efficient method for generation of therapeutic quality human ...
    Sep 10, 2014 · Induced pluripotent stem cell nuclear transfer (iPSCNT) combines the efficiency of iPSC generation with the speed and natural reprogramming environment of SCNT.
  165. [165]
    Stem cell therapies and benefaction of somatic cell nuclear transfer ...
    May 12, 2021 · MSCs confer potential benefits to develop various cell types and organoids for studying virus-human interaction, drug testing, regenerative ...
  166. [166]
    Engineered mitochondria in diseases: mechanisms, strategies, and ...
    Mar 3, 2025 · Mitochondrial replacement therapy (MRT). MRT was initially conceived to address infertility in older women and subsequently refined to ...
  167. [167]
    Mitochondrial Replacement Therapy: In Whose Interests? - PMC
    While the primary aim of MRT is to prevent mitochondrial diseases, the technology could also be used to “treat” infertility. The claim that MRT maybe a new ...
  168. [168]
    Transient non-integrative expression of nuclear reprogramming ...
    Mar 24, 2020 · Here we show that transient expression of nuclear reprogramming factors, mediated by expression of mRNAs, promotes a rapid and broad amelioration of cellular ...
  169. [169]
    Cellular reprogramming and epigenetic rejuvenation
    Sep 6, 2021 · Here, we review the development and potential of reprogramming-induced rejuvenation as an anti-ageing strategy.
  170. [170]
    Chemically induced reprogramming to reverse cellular aging
    Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells. Nat Commun. 2020; 11:1545 ...
  171. [171]
    The Complexities of Interspecies Somatic Cell Nuclear Transfer - MDPI
    iSCNT and SCNT technologies aim to reprogram somatic donor nuclei into a totipotent state, mimicking the developmental processes of a fertilized zygote [30].
  172. [172]
    Stem cell therapies and benefaction of somatic cell nuclear transfer ...
    May 12, 2021 · SCNT initially introduced in 1952 to discover embryo development in frogs came into broad publicity in 1997 when Prof. Ian Wilmut and his team ...<|control11|><|separator|>
  173. [173]
    Human Cloning and Human Dignity: An Ethical Inquiry
    The Council holds unanimously that cloning-to-produce-children is unethical, ought not to be attempted, and should be indefinitely banned by federal law.
  174. [174]
    Cloning humans? Biological, ethical, and social considerations - PMC
    Human cloning would still face ethical objections from a majority of concerned people, as well as opposition from diverse religions. Moreover, there remains the ...
  175. [175]
    Somatic cell nuclear transfer: Past, present and future perspectives
    Aug 6, 2025 · Compared to the live birth rate of over 40% with embryos produced through in vitro fertilization (IVF) (Campbell et al., 2007) , the ...
  176. [176]
    METTL3 improves the development of somatic cell nuclear transfer ...
    We demonstrated that METTL3 overexpression rescued the karyokinesis abnormalities, enhanced embryonic development and elevated the blastocyst formation rate.Mettl3 Improves The... · Introduction · Injection Of Mettl3 Mrna...